ImPACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window >full story
August 13, 2008
BrainsGate raises $27.5m
This is the first investment in Israel in over a year by Johnson & Johnson's VC arm.
by Gali Weinreb >full story
Login
